File Download
  Patent History
  • Application
    PC T/US2002029003 2002-09-13
  • Publication
    WO 03025124 2003-03-27
Supplementary

published patent: IMMUNOGLOBULIN HAVING PARTICULAR FRAMEWORK SCAFFOLD AND METHODS OF MAKING AND USING

TitleIMMUNOGLOBULIN HAVING PARTICULAR FRAMEWORK SCAFFOLD AND METHODS OF MAKING AND USING
Priority Date2001-09-14 US 09/318904P
Inventors
Issue Date2003
Citation
WO Published patent application WO 03025124. World Intellectual Property Organization (WIPO), PatentScope, 2003 How to Cite?
AbstractThis invention relates to immunoglobulin molecules comprising light chain (VL) chimeric variable domains, heavy chain (VH) chimeric variable domains, e.g., scFv antibodies that are expressed at high levels within a host cell, preferably within particular cellular compartments such as, e.g., cytosol or apoplast. The VL, VH and scFv antibody molecules comprise framework scaffolds of particularly preferred framework regions. This invention also relates to nucleic acid molecules encoding the immunoglobulin molecules of this invention, vectors expressing the immunoglobulin molecules, hosts transformed with the nucleic acid molecules and vectors, and methods of using the immunoglobulin molecules. Also described are immunoglobulin libraries as well as host cells, including transgenic plants, expressing the VL, VH or scFv antibody molecules of this invention.
Persistent Identifierhttp://hdl.handle.net/10722/194057
References

 

DC FieldValueLanguage
dc.date.accessioned2014-01-29T05:23:44Z-
dc.date.available2014-01-29T05:23:44Z-
dc.date.issued2003-
dc.identifier.citationWO Published patent application WO 03025124. World Intellectual Property Organization (WIPO), PatentScope, 2003en_US
dc.identifier.urihttp://hdl.handle.net/10722/194057-
dc.description.abstractThis invention relates to immunoglobulin molecules comprising light chain (VL) chimeric variable domains, heavy chain (VH) chimeric variable domains, e.g., scFv antibodies that are expressed at high levels within a host cell, preferably within particular cellular compartments such as, e.g., cytosol or apoplast. The VL, VH and scFv antibody molecules comprise framework scaffolds of particularly preferred framework regions. This invention also relates to nucleic acid molecules encoding the immunoglobulin molecules of this invention, vectors expressing the immunoglobulin molecules, hosts transformed with the nucleic acid molecules and vectors, and methods of using the immunoglobulin molecules. Also described are immunoglobulin libraries as well as host cells, including transgenic plants, expressing the VL, VH or scFv antibody molecules of this invention.en_US
dc.relation.isreferencedbyWO 03054021 (A2) 2003-07-03en_US
dc.relation.isreferencedbyWO 03054021 (A3) 2004-02-12en_US
dc.titleIMMUNOGLOBULIN HAVING PARTICULAR FRAMEWORK SCAFFOLD AND METHODS OF MAKING AND USINGen_US
dc.typePatenten_US
dc.description.naturepublished_or_final_version-
dc.contributor.inventorZHANG, MEI YUNen_US
dc.contributor.inventorSCHILLBERG, STEFANen_US
dc.contributor.inventorZIMMERMANN, SABINEen_US
dc.contributor.inventorDI FIORE, STEFANOen_US
dc.contributor.inventorEMANS, NEILen_US
dc.contributor.inventorFISCHER, RAINERen_US
patents.identifier.applicationPC T/US2002029003en_US
patents.description.assigneeFRAUNHOFER INST MOLEKULARBIOLO [DE]; ZHANG MEI YUN [US]; SCHILLBERG STEFAN [DE]; ZIMMERMANN SABINE [DE]; DI FIORE STEFANO [DE]; EMANS NEIL [BE]; FISCHER RAINER [DE]en_US
patents.description.countryWorld Intellectual Property Organization (WIPO)en_US
patents.date.publication2003-03-27en_US
dc.relation.referencesWO 9109967 (A1) 1991-07-11en_US
dc.relation.referencesXP 001023515en_US
patents.date.application2002-09-13en_US
patents.date.priority2001-09-14 US 09/318904Pen_US
patents.description.ccwoen_US
patents.identifier.publicationWO 03025124en_US
patents.relation.familyAU 2002324973 (A1) 2003-04-01en_US
patents.relation.familyEP 1434800 (A2) 2004-07-07en_US
patents.relation.familyUS 2005037420 (A1) 2005-02-17en_US
patents.description.kindA2en_US
patents.typePatent_publisheden_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats